KP Rx | Activity | F4KP Rx Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Talk
Hosted a 2026 outlook webinar discussing portfolio company Syntara.
Syntara
Founder Hashan De Silva discussed keys to successful life science investing.
Hashan De Silva - Keys to Successful Life Science Investing
Press
Video interview discussing KP Rx's inflection-point investment strategy in healthcare.
Investing at the inflexion point in healthcare innovation
Essay
Published a thesis essay on backing world-class Australian biotech companies.
Punching above our weight: backing world-class Aussie biotechs
Press
Livewire roundup featuring KP Rx's most-excited-about biotech picks.
The 4 biotech firms the experts are most excited about
Milestone
Livewire profiled portfolio company CurveBeam AI's growth positioning as an ASX medtech innovator.
CurveBeam AI
Milestone
Livewire covered portfolio company Syntara's value-unlocking catalysts.
Syntara
4 presss· MAY 2024 – SEP 2024Show all
Press
Livewire roundup featuring KP Rx's biotech stock picks and trial catalysts to watch.
The 7 biotech stocks (and their trials) these experts are watching right now
Press
Livewire featured KP Rx's view on healthcare market conditions.
Could this be the best market ever for healthcare investing?
Press
NBR New Zealand interviewed KP Rx on cross-border investment policy between Australia and New Zealand.
Aussie VC investor wants liberalisation of trans-Tasman market
Press
The Australian reported on KP Rx scaling back its $200M fund target amid market conditions.
Investor who bought Neuren at $1 a share lowers sights on $200m fund
Essay
Published an investment thesis essay on healthcare sector timing and valuations.
Be greedy when others are fearful: Why now is the time to invest in healthcare
Press
Livewire interviewed Hashan De Silva about his early investment track record in Neuren Pharmaceuticals.
This fundie invested in Neuren at a $70m valuation. It's now $2.4 billion.
Press
Livewire profiled KP Rx's healthcare investment strategy and cornerstone investor backing.
Backed by industry titans, leveraging Australia's healthcare innovation